VHH as Agonists & Antagonists
Antagonist/agonist VHH antibodies have their ability to modulate the activity of the signalling pathways, making them potentially useful in the treatment of many diseases.
VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
VHH as Agonists & Antagonists Resources
Isogenica’s PD-L1 VHH as
OCTOBER 13, 2021
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. The interaction between PD-1 and PD-L1 can be both beneficial and harmful…
Anti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
APRIL 26, 2021
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery…
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.